Cabell Christopher bought IKT
January 5, 2026 · Form 4 insider transaction
Cabell Christopher bought 900,117 shares of Inhibikase Therapeutics, Inc. at $0.00 per share, a transaction worth N/A. The trade was recorded as grant or award and disclosed on an SEC Form 4, filed 2 days after the transaction.
Direction
Acquired (buy-side)
Shares
900,117
Price
$0.00
Total value
N/A
InsiderCabell Christopher
RoleOfficer
SecurityStock Option (Right to Buy)
Transaction codeA: Grant or award
Transaction dateJanuary 5, 2026
Filing dateJanuary 7, 2026
Shares owned after900,117
OwnershipDirect
10b5-1 planNo
AmendedNo
Footnotes
The shares underlying the option shall vest and become exercisable in 36 equal monthly installments commencing from January 5, 2026, subject to the Reporting Person's continued employment through each such vesting date.